NORWALK, Conn., Aug. 25, 2014 /PRNewswire/ -- UBM Medica US announces that EndocrinologyNetwork, a leading online community for endocrinologists and other clinicians who treat patients with T2DMoffers a comprehensive coverage on the SGLT2 inhibitors.
Another day, another new drug to treat type 2 diabetes (T2DM) at least that’s the way it may seem to some physicians shouldering the therapeutic burden of caring for the 28.5 million persons with the disease in the United States. In May, another new agent was added to the newest class of oral antihyperglycemic agentsthe sodium-glucose cotransporter 2 (SGLT2) inhibitors. The mechanism of action of these drugs is unlike any currently available and will require ongoing clinical education.
Some highlights of SGLT2 Inhibitor coverage include:
- SGLT2 Inhibitors: Mechanism of Action, Pros, and Cons: Sodium glucose cotransporter 2 inhibitors act independently of insulin level and so can be used at various stages of type 2 diabetes disease progression.
- Whole-Body Metabolic Response to SGLT2 Inhibition: Benefit or Risk? Research on the new agents reveals an apparently paradoxical response to the glycosuria induced by the drugs.
- SGLT2 Inhibitors: 5 Things You Should Know: FDA approval of a third sodium-glucose cotransporter 2 inhibitor steepens the learning curve for these agents.
- SGLT2 Inhibitors: 4 Points on Efficacy, Safety You Need to Know: This concise slide show highlights results of clinical trials that studied add-on treatment with SGLT2 inhibitors and how to adjust their dosing for renal impairment.
About UBM Medica US
Addressing today’s healthcare information needs, UBM Medica US, delivers strategic, integrated communications solutions and comprehensive reach -- online, in print, via custom programs and live events. Improving the effectiveness of healthcare through information and education, UBM Medica US provides unbiased clinical, practical, and business information for physicians, providers and payers resulting in improved quality of care for patients around the world. Through journals, magazines, online communities, live and digital events, and other valuable resources, UBM Medica US also delivers comprehensive communication solutions for the pharmaceutical and related industries. Online communities include CancerNetwork.com, ConsultantLive.com, DiagnosticImaging.com, RheumatologyNetwork.com, OBGYN.net, PhysiciansPractice.com, PsychiatricTimes.com and SearchMedica.com. UBM Medica US is part of UBM Connect which, through a range of aligned interactive environments, both physical and digital increases business effectiveness for both customers and audiences through meaningful experiences, knowledge and connections. Headquartered in New York, UBM Connect brings together UBM’s healthcare business, UBM Medica US; UBM Canon’s advanced design and manufacturing event, online and print brands; UBM Connect New York’s catering, cruise shipping, contact-center management, and fine, specialty and custom chemical communities; and UBM Mexico’s concrete, construction and hospitality services shows. For more information, visit www.UBMMedicaUS.com.
About UBM plc
UBM plc is a global events-led marketing services and communications company. We help businesses do business, bringing the world’s buyers and sellers together at events and online, as well as producing and distributing news and specialist content. Our 5,500 staff in more than 30 countries are organized into expert teams which serve commercial and professional communities, helping them to do business and their markets to work effectively and efficiently.
For more information, go to www.ubm.com; follow us on Twitter at @UBM_plc to get the latest UBM corporate news.
Media contact:
Jason J. Golden
Content Marketing Manager
203-523-7040
jason.golden@ubm.com
SOURCE UBM Medica US
Help employers find you! Check out all the jobs and post your resume.
